-
2
-
-
0032414730
-
Capecitabine: A novel oral tumor-activated fluoropyrimidine
-
2. Frings S. Capecitabine: a novel oral tumor-activated fluoropyrimidine. Onkologie 1998; 21: 451-8
-
(1998)
Onkologie
, vol.21
, pp. 451-458
-
-
Frings, S.1
-
3
-
-
0031730625
-
Oral 5-FU analogues in the treatment of breast cancer
-
3. Bunnell C, Winer E. Oral 5-FU analogues in the treatment of breast cancer. Oncology 1998; 12 (10 Suppl. 7): 39-43
-
(1998)
Oncology
, vol.12
, Issue.10 SUPPL. 7
, pp. 39-43
-
-
Bunnell, C.1
Winer, E.2
-
4
-
-
0031788357
-
The oral fluouracil pro-drugs
-
4. Pazdur R, Hoff P, Medgyesy D, et al. The oral fluouracil pro-drugs. Oncology 1998; 12 (10 Suppl. 7): 48-51
-
(1998)
Oncology
, vol.12
, Issue.10 SUPPL. 7
, pp. 48-51
-
-
Pazdur, R.1
Hoff, P.2
Medgyesy, D.3
-
5
-
-
0032127244
-
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
-
5. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34 (8): 1274-81
-
(1998)
Eur J Cancer
, vol.34
, Issue.8
, pp. 1274-1281
-
-
Miwa, M.1
Ura, M.2
Nishida, M.3
-
6
-
-
0031858552
-
4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine)
-
4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 1998; 21 (7): 713-7
-
(1998)
Biol Pharm Bull
, vol.21
, Issue.7
, pp. 713-717
-
-
Ishikawa, T.1
Fukase, Y.2
Yamamoto, T.3
-
7
-
-
0032520168
-
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
-
Feb 15
-
7. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998 Feb 15; 58: 685-90
-
(1998)
Cancer Res
, vol.58
, pp. 685-690
-
-
Ishikawa, T.1
Sekiguchi, F.2
Fukase, Y.3
-
8
-
-
0031944611
-
Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
-
Apr
-
8. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998 Apr; 4: 1013-9
-
(1998)
Clin Cancer Res
, vol.4
, pp. 1013-1019
-
-
Sawada, N.1
Ishikawa, T.2
Fukase, Y.3
-
9
-
-
0344541873
-
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
-
9. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55: 1091-7
-
(1998)
Biochem Pharmacol
, vol.55
, pp. 1091-1097
-
-
Ishikawa, T.1
Utoh, M.2
Sawada, N.3
-
10
-
-
0031859855
-
Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
-
May
-
10. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998 May; 16 (5): 1795-802
-
(1998)
J Clin Oncol
, vol.16
, Issue.5
, pp. 1795-1802
-
-
Budman, D.R.1
Meropol, N.J.2
Reigner, B.3
-
11
-
-
0031671094
-
Phase I and pharmalogic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
-
11. Mackean M, Planting A, Twelves C, et al. Phase I and pharmalogic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16 (9): 2977-85
-
(1998)
J Clin Oncol
, vol.16
, Issue.9
, pp. 2977-2985
-
-
Mackean, M.1
Planting, A.2
Twelves, C.3
-
12
-
-
0031724433
-
A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
-
12. Cassidy J, Dirix L, Bissett D, et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998; 4: 2755-61
-
(1998)
Clin Cancer Res
, vol.4
, pp. 2755-2761
-
-
Cassidy, J.1
Dirix, L.2
Bissett, D.3
-
13
-
-
0000267974
-
Tumor selective activation of capecitabine in colorectal cancer patients
-
Oct
-
13. Schüller J, Cassidy J, Reigner B, et al. Tumor selective activation of capecitabine in colorectal cancer patients [abstract]. Onkologie 1997 Oct; 20 Suppl. 1: 189
-
(1997)
Onkologie
, vol.20
, Issue.SUPPL. 1
, pp. 189
-
-
Schüller, J.1
Cassidy, J.2
Reigner, B.3
-
14
-
-
0033050165
-
Multicenter phase II study of capecitabine in pactitaxel-refractory metastatic breast cancer
-
Feb
-
14. Blum J, Jones S, Buzdar A, et al. Multicenter phase II study of capecitabine in pactitaxel-refractory metastatic breast cancer. J Clin Oncol 1999 Feb; 17 (2): 485-93
-
(1999)
J Clin Oncol
, vol.17
, Issue.2
, pp. 485-493
-
-
Blum, J.1
Jones, S.2
Buzdar, A.3
-
15
-
-
0001432831
-
A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
-
May 16
-
15. O'Reilly SM, Moiseyenko V, Talbot DC. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy [abstract]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 163a
-
(1998)
34th Proc Am Soc Clin Oncol
, vol.17
-
-
O'Reilly, S.M.1
Moiseyenko, V.2
Talbot, D.C.3
-
16
-
-
0000709431
-
A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged greater than or equal to 55 years
-
May 16
-
16. O'Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged greater than or equal to 55 years [abstract]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 103a
-
(1998)
34th Proc Am Soc Clin Oncol
, vol.17
-
-
O'Shaughnessy, J.1
Moiseyenko, V.2
Bell, D.3
|